Changes for page BioPharmX Corporation

Last modified by Asif Farooqui on 2019/09/30 13:52
From version < 2.2 >
edited by Asif Farooqui
on 2019/09/30 13:51
To version < 3.1
edited by Asif Farooqui
on 2019/09/30 13:52
<
Change comment: There is no comment for this version

Summary

Details

Page properties
Content
... ... @@ -10,16 +10,16 @@
10 10  
11 11  In April 2017, the company raised net proceeds of $4.4 million in a registered direct offering of 6,410,258 shares of common stock and warrants to purchase up to 3,365,385 shares of its common stock. In July 2017, the company raised net proceeds of $1.9 million in a registered direct offering of 5,500,000 shares of its common stock.
12 12  
13 -==== BioPharmX Corporate Highlights ====
13 += BioPharmX Corporate Highlights =
14 14  
15 -**Unique Drug Delivery Systems in Dermatology**
15 +== Unique Drug Delivery Systems in Dermatology ==
16 16  
17 17  Multiple platforms focused on delivery of API to precise targets optimizing safety and efficacy Hydrophilic Topical Delivery System offers sustainable pipeline of products with known API, reduces regulatory timeline, cost and risk Technology developed in-house
18 18  
19 -**BPX-01 Lead Indication – Acne**
19 +== BPX-01 Lead Indication – Acne ==
20 20  
21 21  Completed positive Phase 2 for acne vulgaris First non-lipophilic topical antibiotic formulation of Minocycline FDA meeting requested; planning for phase 3 ongoing
22 22  
23 -**BPX-01 Second Indication - Rosacea**
23 +== BPX-01 Second Indication - Rosacea ==
24 24  
25 25  Established feasibility; planning for phase 2/3 Confirmed tolerability in multiple doses
This site is funded and maintained by Fintel.io